DBCO-Val-Cit-OH
This product is a heterobifunctional linker featuring a dibenzocyclooctyne (DBCO) group for copper-free SPAAC click chemistry and a Val–Cit dipeptide for protease-cleavable drug release. This design offers bioorthogonal reactivity and tumor-selective cleavage, making it especially valuable in ADC development, drug delivery, and bioconjugation.
Key Features and Benefits:
-
DBCO Group: Enables catalyst-free SPAAC click chemistry with azides.
-
Val–Cit Dipeptide: Cleaved by cathepsin B in tumor microenvironments.
-
Self-Immolative Design: Supports payload release in therapeutic systems.
-
PEGylated Scaffold: Improves solubility and flexibility.
-
High Purity: Ensures reliable performance in therapeutic and research applications.
Applications:
-
Antibody–Drug Conjugates (ADCs): Provides tumor-selective cleavable linkers.
-
Drug Delivery: Supports targeted release of therapeutic agents.
-
Probe Development: Enables bioorthogonal and enzyme-responsive probe design.
-
Bioconjugation: Combines SPAAC chemistry with protease-sensitive release.
Storage and Handling:
-
Storage: Store at –20 °C in a sealed, light- and moisture-protected container.
-
Handling: Use anhydrous solvents (e.g., DMF, DMSO); avoid prolonged hydrolysis.
This product combines SPAAC-ready DBCO chemistry with a protease-cleavable Val–Cit linker, specifically offering solubility and targeted release functionality for advanced conjugation strategies.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
